Need help navigating aged care? Explore our support services
Aged Care Home
Support at Home
Retirement Living
Finance & Placement Advice
Healthcare Equipment
Mobility and Equipment
Patient care equipment
Skin and wound Care
Safety and Security
Assessments
Assistive Technology
End of Life
Financial Services
Funerals
Placement Consultants
Advocacy
No results found
No results found
No results found
Advanced Filters
Distance (proximity)
Price Range
RAD (Refundable Accommodation Deposit) is a lump-sum payment for aged care homes. It is fully refundable when the resident leaves, as long as there are no outstanding fees.
Min RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Maximum RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Facility size
Based on how many beds the facilty has.
Any
Small
Medium
Large
Service Delivery
Services offered at a location or in a region
Any
On Site
Service Region
Features
Single rooms with ensuites
Respite beds
Extra service beds
Secure dementia beds
24/7 Registered nursing
Full or Partially government funded
Couples accommodation
Facility has pets
Non-dedicated respite
Palliative care
Partner considered without ACAT
Secure garden
Transition care
Cafe/Kiosk
Chapel/Church
Hairdressing Salon
Facility Owned Transport
Single Rooms
Rooms with ensuites
Registered nursing
Non secure dementia care
Diversional therapy
Medication supervision
Respite care
Secure access
Small pets considered

New medication guidelines put individuals before illness

The issue of unnecessary prescription of medications in older Australians living with dementia is expected to be addressed following the release of new guidelines by the National Health and Medical Research Council (NHMRC).

Posted
by Grace Mindwell
<p>Dementia Australia has endorsed new medication guidelines (Source: Shutterstock)</p>

Dementia Australia has endorsed new medication guidelines (Source: Shutterstock)

The newly approved guidelines aim to assist healthcare professionals to determine when it might be suitable to trial the withdrawal of medications when treating people with dementia.

Centre for Medicine Use and Safety Professor Simon Bell says there is increasing evidence about the value of proactively discontinuing medicines for which the potential benefits no longer outweigh the potential risks.

“The guideline provides clinicians, consumers and carers with new recommendations regarding the withdrawal of cholinesterase or memantine,” he explains.

“In particular, the guideline highlights the important role people with dementia and their carers in deciding whether or not to trial discontinuation.”

Dementia Australia Chief Executive Officer Maree McCabe has stepped out as an “advocate” for the 425,000 Australians and their families impacted by dementia, to share the peak advocacy body’s support of the new initiative.

She says Dementia Australia is “encouraged” by the release of the guidelines that “recognise that the experience of people living with dementia is individual and unique”.

“While there are certainly instances where the prescription of ongoing and multiple medications is beneficial for people living with dementia, this is not always the case,” she says.

“Over time, certain medications can lose their effectiveness and they can hinder quality of life rather than improve it.

“As for any change in treatment and as recommended in the guidelines, the withdrawal of medication should be discussed between the healthcare professional, the individual and their carer to ensure the individual and their carer are informed of the potential harm and benefits of continuing or discontinuing use – good communication is critical.

“These guidelines put individuals’ values, preferences and experiences ahead of their illness.

“What’s important now is that these guidelines are read and considered by all clinicians.”

Read next

Sign up or log in with your phone number
Phone
Enter your phone number to receive a verification notification
Aged Care Guide is endorsed by
COTA logo
ACIA logo